Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Moodys
AstraZeneca
McKesson
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Chubb
Chinese Patent Office
Baxter

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,840,684 protect, and when does it expire?


Patent ► Subscribe protects ORBACTIV and is included in one NDA.

This patent has sixty-one patent family members in thirty countries.

Summary for Patent: ► Subscribe

Title: Glycopeptide antibiotic derivatives
Abstract:The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
Inventor(s): Cooper; Robin D. G. (Indianapolis, IN), Huff; Bret E. (Mooresville, IN), Nicas; Thalia I. (Indianapolis, IN), Quatroche; John T. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN), Snyder; Nancy J. (Charlottesville, IN), Staszak; Michael A. (Indianapolis, IN), Thompson; Richard C. (Frankfort, IN), Wilkie; Stephen C. (Indianapolis, IN), Zweifel; Mark J. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/410,155
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeYY TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,843,889 Glycopeptide antibiotic derivatives► Subscribe
5,977,062 Glycopeptide antibiotic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil9500365► Subscribe
Canada2141106► Subscribe
Canada2216167► Subscribe
Canada2546625► Subscribe
Canada2546910► Subscribe
China1119649► Subscribe
China1071334► Subscribe
Colombia4600679► Subscribe
Czech Republic9500184► Subscribe
Czech Republic292895► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Johnson and Johnson
Moodys
Medtronic
Baxter
AstraZeneca
Harvard Business School
UBS
Mallinckrodt
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot